make things clear and consistent and maximize impact" (Cochrane brand, 2019a) . The latest brand guidelines is a 144-page document that details what to do and say and what not, and with suggestions on how to describe the charity, its history and its current efforts and visions with many beautiful words (Cochrane brand, 2019b) .
It seems to undersigned that this initially idealistic charity has contracted some form of Icarus syndrome prompted by seduction to generate substantial revenues rather than strengthening the actual value of the offered products, i.e., the access to the databases of RCTs and systematic reviews (SR) and quality assurance of the latter category. Moreover, from a research ethics perspective, one may question why the Cochrane Collaboration has still not established a policy not to include in SRs primary studies that fail to report an approval by an ethics committee or institutional review board (Jokstad, 2017) .
The charity has repeatedly stated that one of the main goals is to make evidence accessible and useful to everybody, everywhere in the world. However, this is not compatible with the current position on open access (OA) which is: " … maintaining and expanding Cochrane Library revenues" (Cochrane, 2019) . The initiative for OA launched by Science Europe in September 2018 seems not to be on the agenda within the Cochrane Collaboration, as judged by a search on their website. (Alternatively, the website search index has not been reindexed lately). True, since 2013 a hybrid ("green") access policy has been in place, i.e., a 12 months embargo followed by open access, alternatively an option for the authors of SRs to pay an articleprocessing charge (APC) of $5000 for full ("gold") access (Cochrane Open Access, 2019) . This arrangement does not set the charity apart and is analogue to the practices of most commercial publishers.
Moreover, the APC is higher than the APC of most commercial publishers. The multiple "news" infrequently on Cochrane.org/news about this and that country now having free access to Cochrane The "value" of the Cochrane SRs is a reputation of comprehensiveness and objectivity, which encompasses a thorough search for trials and an impartial assessment of the identified evidence that include estimations of the likelihood of bias. They may perhaps be trustworthy, but they are not truths. Rather, they are best guesses, sometimes including a range of uncertainty. When it comes to the likelihood of being false, a meta-analysis of small, inconclusive studies is statistically likely to have a positive predictive value (PPV, or false positive finding) that is below 50% under most premises (Ioannidis, 2005) . wileyonlinelibrary.com/journal/cre2caution is needed before scale-up of antenatal corticosteroids to reduce preterm deaths in low-income settings" (Azad & Costello, 2014) , which seriously jolted the confidence of doing more good than harm. WHO convened very rapidly an expert group, which concluded that the generalisability of the available evidence demonstrate that a true state of clinical equipoise exists for this treatment option in low-resource settings and that there was a clear need for more efficacy trials of ACS in these settings (Vogel et al., 2017) . Also, the latest Admittedly, it seems very logical that by conducting a metaanalysis on a set of RCTs judged to be "true", one may derive an estimate of effectiveness we believe is "trustworthy", given that a choice of potential biases has been identified and considered.
Unfortunately, this idea is not so simple from a statistical perspective for at least two reasons.
The first reason is that effect estimations in most meta-analyses leave out the element of random errors between the studies, e.g., as a reflection of small sample size and methodological heterogeneity combined with multiple testing. One may approximate that seemingly conclusive meta-analyses become inconclusive (Brok, Thorlund, Wetterslev, & Gluud, 2009 ) after applying statistical methods termed recursive cumulative meta-analysis (Ioannidis, Contopoulos-Ioannidis, & Lau, 1999) or trial sequential analyses (TSA) (Wetterslev, Thorlund, Brok, & Gluud, 2008) . Only a distinct minority of Cochrane SRs include TSA-analyses. Hence, "trusted evidence" may not be so trustworthy after all, even if it comes from the Cochrane Collaboration, which emphasizes once again that in science, one may never prove anything, but rather one can disprove theories with a precise (low) level of probability.
Secondly, the practice of appraising only "quality-trials" and stratifying meta-analyses according to perceived bias has been criticized for at least two decades. Already in 1999, a group of authoritative epidemiologists used regression models to examine whether the type of quality assessment scale being used affected the conclusions of meta-analytic studies. Their advice from their findings was "..that the use of summary scores to identify trials of high quality is problematic" (Jüni, Witschi, Bloch, & Egger, 1999) . Twenty years later, another group of authoritative epidemiologists question why this practice is still maintained in Cochrane SRs since "stratification by quality leads to a form of selection bias, i.e., collider-stratification bias, and should be avoided" in favor of other approaches (Stone et al., 2019) .
A critical take-home message is that some SRs present only amalgamated facts, while others also give their interpretations of the facts.
These interpretations are invariably primed by their authors' theories, values, and ideologies (Wieringa, Engebretsen, Heggen, & Greenhalgh, 2018 ). It takes a trained mindset to perceive the almost imperceptible border between these two types of SRs. Proponents of compiling SRs that fit the first category can argue that non-content experts can write adequate SRs and that even in some circumstances, avoiding content experts as co-authors can be an advantage (Gøtzsche & Ioannidis, 2012 Regardless, a strategy that gives an impression of the charity becoming some sort of a moneymaking enterprise that rival "competitors" should be abandoned. It is astonishing that a statement on www: "Anyone who produces, or who finds a way to make systematic reviews more digestible and more relevant to the audience, is in competition with Cochrane" is attributed to the CEO of the charity.
In contrast, my persuasion is that most health care providers and patients would like the charity to work together with and not compete with "anyone" for the betterment of health care.
